HUTCHMED (China) Ltd
H7T1
Company Profile
Business description
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Contact
2 Queen's Road Central
48th Floor, Cheung Kong Center
Hong Kong
HKGT: +852 2121 8200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,796
Stocks News & Analysis
stocks
Anthropic and OpenAI face commodification threats. Here’s what to watch for
Frontier AI labs face a three-pronged set of challenges.
stocks
Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment
We think it is a sign that the firm is finally moving out of its comfort zone to find places to put capital to work.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,944.20 | 31.50 | -0.35% |
| CAC 40 | 7,865.01 | 3.04 | -0.04% |
| DAX 40 | 25,363.29 | 43.52 | 0.17% |
| Dow JONES (US) | 52,590.26 | 624.23 | 1.20% |
| FTSE 100 | 10,740.38 | 24.31 | -0.23% |
| HKSE | 23,867.74 | 319.09 | -1.32% |
| NASDAQ | 26,554.78 | 123.89 | 0.47% |
| Nikkei 225 | 64,075.42 | 841.28 | -1.30% |
| NZX 50 Index | 13,631.69 | 20.38 | -0.15% |
| S&P 500 | 7,737.56 | 46.83 | 0.61% |
| S&P/ASX 200 | 8,816.90 | 28.80 | -0.33% |
| SSE Composite Index | 3,735.37 | 4.45 | 0.12% |